$XLO

$7.31 -$0.26 (3.43%) Close

$XLO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 19.4M shares outstanding

Who owns XLO?

By type of holder

Institutions 17.6% Insiders 7.0% Everyone else 75.4%

Concentration Top 10 holders own 17.7%

Bain Capital Life Sciences Investors, LLC 3.4% · Gilead Sciences, Inc. 3.4%

Institutional ownership

17.6%

+4.1 pts vs last qtr

Institutional holders

+3 vs last qtr

Net shares bought

+787.8K

by institutions in Q2 2026

New / sold out

11 / 8

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Orbimed Advisors LLC NEW +592.3K
Stonepine Capital Management, LLC +161.8K

Biggest sellers in Q2 2026

Caligan Partners LP SOLD OUT −112.1K
AJU IB Investment Co., Ltd. SOLD OUT −47.7K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Xilio Therapeutics Inc in the last 12 months.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Xilio Therapeutics Inc.

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years30% 1–3 years22% Under 1 year47%

Quarterly turnover

23.8%

of institutional shares changed hands

Top 10 managers, median time held

1.5 years

Super Investors

Investment managers reporting XLO on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
BC Bain Capital Life Sciences Investors, LLC	664.0K	3.42%	Unchanged	2021	0.4%
Shares held by quarter Peak holding7.4M (Q4'25) Change over 8 quarters−3.9M Share of the company3.420% Bain Capital Life Sciences Investors, LLC's full portfolio →
GS Gilead Sciences, Inc.	650.4K	3.35%	Unchanged	2024	0.4%
Shares held by quarter Peak holding9.1M (Q4'24) Change over 8 quarters+650.4K Share of the company3.350% Gilead Sciences, Inc.'s full portfolio →

Bain Capital Life Sciences Investors, LLC

664.0K

% of company

3.42%

Change vs last qtr

Unchanged

Held since

2021

Gilead Sciences, Inc.

650.4K

% of company

3.35%

Change vs last qtr

Unchanged

Held since

2024

28 more super investors behind a free account

See every manager holding Xilio Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting XLO on Form N-PORT; together they hold 1.2% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$1.36M	142.4K	0.73%	0.00%	June 30, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$341K	35.6K	0.18%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$1.36M

% of company

0.73%

% of the fund

0.00%

As of

June 30, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$341K

% of company

0.18%

% of the fund

0.00%

As of

June 30, 2026

12 more funds behind a free account

See every fund holding Xilio Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
RR Russo Rene Insider	325.4K	1.68%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.680% Russo Rene's insider activity →
LK Luptakova Katarina Insider	33.3K	0.17%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.170% Luptakova Katarina's insider activity →

Russo Rene

Insider

325.4K

% of company

1.68%

Change vs last qtr

—

Held since

—

Luptakova Katarina

Insider

33.3K

% of company

0.17%

Change vs last qtr

—

Held since

—

3 more holders behind a free account

See every insider and 5%+ holder of Xilio Therapeutics Inc.

Comments